{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:43:13Z","timestamp":1787931793576,"version":"build-2784847793"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Guard Therapeutics International AB"},{"name":"Universit\u00e4tsklinikum M\u00fcnster"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cardiac surgery with cardiopulmonary bypass invariably induces renal stress and risk of irreversible kidney function loss, with no approved drug treatments. RMC-035, a recombinant human alpha-1-microglobulin with potent heme-binding and antioxidant capacity, has shown promising long-term kidney-protective effects in a phase 2a trial of patients undergoing cardiac surgery. The primary objective of this phase 2b dose-optimisation trial is to demonstrate that RMC-035 (pooled dose groups) is superior to placebo in preserving renal function at 90\u00a0days after surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This randomised, blinded, placebo-controlled, multicentre study evaluates the efficacy and safety of RMC-035 among approximately 161 high-risk patients undergoing cardiac surgery who are randomised into one of three treatment groups in a 2:2:3 ratio: RMC-035 (30\u00a0mg or 60\u00a0mg) or placebo. The study drug is administered via three intravenous infusions, with the first dose given intraoperatively, followed by additional doses at 6 and 24\u00a0h, respectively. The primary endpoint is the change in estimated glomerular filtration rate (eGFR) from baseline (pre-surgery) to Day 90. Important secondary endpoints include the incidence of major adverse kidney events at Day 90 and short-term outcomes reflecting changes in renal filtration markers up to Day 7. Safety assessments encompass adverse events, vital signs, electrocardiograms and routine safety laboratory tests. Additional evaluations include pharmacokinetics, anti-drug antibodies and immunological biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This multicentre, multinational phase 2b trial, will assess the change in eGFR within 90\u00a0days of the first dose, providing additional evidence of the long-term kidney-protective potential of RMC-035 in patients undergoing cardiac surgery at high risk for kidney injury. Trial outcomes will inform the preferred dose, dosing regimen, and benefit-risk profile related to cardiac surgery for a future pivotal phase 3 trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      The trial was registered June 20, 2024, at Clinicaltrials.gov (NCT06475274\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT06475274\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/study\/NCT06475274<\/jats:ext-link>\n                      ). The trial including the participating EU countries is also registered with the EUCT number 2024\u2013510658-28 under\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/euclinicaltrials.eu\/search-for-clinical-trials\/?lang=en&amp;EUCT=2024-510658-28-00\" ext-link-type=\"uri\">https:\/\/euclinicaltrials.eu\/search-for-clinical-trials\/?lang=en&amp;EUCT=2024-510658-28-00<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                    <jats:p>The first patient was enrolled August 26, 2024.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-025-09124-x","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:24:02Z","timestamp":1761665042000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["POINTER: study protocol for a phase 2b, randomised, placebo-controlled, double-blind, parallel group dose-finding clinical study to evaluate the efficacy of RMC-035 on renal function and safety, in participants at high risk for kidney injury, following open-chest cardiac surgery"],"prefix":"10.1186","volume":"26","author":[{"given":"Alexander","family":"Zarbock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Laflamme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrej","family":"Myjavec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Burkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. David","family":"Mazer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"de Varennes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino Ginel","family":"Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Matschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias E.","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Reusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"POINTER study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"issue":"14","key":"9124_CR1","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1161\/CIRCULATIONAHA.120.053029","volume":"144","author":"M Thielmann","year":"2021","unstructured":"Thielmann M, Corteville D, Szabo G, Swaminathan M, Lamy A, Lehner LJ, et al. Teprasiran, a small interfering RNA, for the prevention of acute kidney injury in high-risk patients undergoing cardiac surgery: a randomized clinical study. Circulation. 2021;144(14):1133\u201344.","journal-title":"Circulation"},{"issue":"1","key":"9124_CR2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.athoracsur.2018.01.066","volume":"106","author":"HR Bouma","year":"2018","unstructured":"Bouma HR, Mungroop HE, de Geus AF, Huisman DD, Nijsten MWN, Mariani MA, et al. Acute Kidney Injury Classification Underestimates Long-Term Mortality After Cardiac Valve Operations. Ann Thorac Surg. 2018Jul 1;106(1):92\u20138.","journal-title":"Ann Thorac Surg"},{"issue":"2","key":"9124_CR3","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/ndt\/gfy227","volume":"34","author":"F Husain-Syed","year":"2019","unstructured":"Husain-Syed F, Ferrari F, Sharma A, Danesi TH, Bezerra P, Lopez-Giacoman S, et al. Persistent decrease of renal functional reserve in patients after cardiac surgery-associated acute kidney injury despite clinical recovery. Nephrol Dial Transplant. 2019Feb 1;34(2):308\u201317.","journal-title":"Nephrol Dial Transplant"},{"key":"9124_CR4","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1172\/JCI45161","volume":"121","author":"JV Bonventre","year":"2011","unstructured":"Bonventre JV, Yang L. Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest. 2011;121:4210\u201321.","journal-title":"J Clin Invest"},{"key":"9124_CR5","doi-asserted-by":"crossref","unstructured":"Von Groote T, Sadjadi M, Zarbock A. Acute kidney injury after cardiac surgery. Curr Opin Anaesthesiol. 2024;37:35\u201341. Lippincott Williams and Wilkins.","DOI":"10.1097\/ACO.0000000000001320"},{"key":"9124_CR6","doi-asserted-by":"crossref","unstructured":"\u00c5kerstr\u00f6m B, Gram M. A1M, an extravascular tissue cleaning and housekeeping protein. Free Radic Biol Med. 2014;74:274\u201382. Elsevier Inc.","DOI":"10.1016\/j.freeradbiomed.2014.06.025"},{"issue":"1","key":"9124_CR7","doi-asserted-by":"publisher","first-page":"F103","DOI":"10.1152\/ajprenal.00067.2024","volume":"327","author":"M Burmakin","year":"2024","unstructured":"Burmakin M, Gilmour PS, Gram M, Shushakova N, Sandoval RM, Molitoris BA, et al. Therapeutic a-1-microglobulin ameliorates kidney ischemia-reperfusion injury. Am J Physiol Renal Physiol. 2024Jul 1;327(1):F103\u201312.","journal-title":"Am J Physiol Renal Physiol"},{"key":"9124_CR8","first-page":"76","volume":"1","author":"A Zarbock","year":"2024","unstructured":"Zarbock A, Larsson TE, Noiseux N, Mazer CD, B\u00f6hm J, Laflamme M, et al. Efficacy and safety of therapeutic alpha-1-microglobulin RMC-035 in reducing kidney injury after cardiac surgery: a multicentre, randomised, double-blind, parallel group, phase 2a trial. EClinicalMedicine. 2024Oct;1:76.","journal-title":"EClinicalMedicine"},{"issue":"19","key":"9124_CR9","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021Nov 4;385(19):1737\u201349.","journal-title":"N Engl J Med"},{"key":"9124_CR10","unstructured":"Kellum JA, Lameire N, Aspelin P, Barsoum RS, Burdmann EA, Goldstein SL, et al. Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1\u2013138. Nature Publishing Group."},{"key":"9124_CR11","doi-asserted-by":"crossref","unstructured":"Singer M, Deutschman CS, Seymour C, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315:801\u201310. American Medical Association.","DOI":"10.1001\/jama.2016.0287"},{"issue":"1","key":"9124_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1114248","volume":"367","author":"LA Inker","year":"2012","unstructured":"Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20\u20139.","journal-title":"N Engl J Med"},{"issue":"8","key":"9124_CR13","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1681\/ASN.2015060687","volume":"27","author":"CP Kovesdy","year":"2016","unstructured":"Kovesdy CP, Coresh J, Ballew SH, Woodward M, Levin A, Naimark DMJ, et al. Past decline versus current EGFR and subsequent ESRD risk. J Am Soc Nephrol. 2016;27(8):2447\u201355.","journal-title":"J Am Soc Nephrol"},{"issue":"24","key":"9124_CR14","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1001\/jama.2014.6634","volume":"311","author":"J Coresh","year":"2014","unstructured":"Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014Jun 25;311(24):2518\u201331.","journal-title":"JAMA"},{"issue":"7","key":"9124_CR15","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S2213-8587(15)00040-6","volume":"3","author":"K Matsushita","year":"2015","unstructured":"Matsushita K, Coresh J, Sang Y, Chalmers J, Fox C, Guallar E, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: A collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015Jul 1;3(7):514\u201325.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"9124_CR16","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1681\/ASN.2019010008","volume":"30","author":"ME Grams","year":"2019","unstructured":"Grams ME, Sang Y, Ballew SH, Matsushita K, Astor BC, Carrero JJ, et al. Evaluating glomerular filtration rate slope as a surrogate end point for ESKD in clinical trials: an individual participant meta-analysis of observational data. J Am Soc Nephrol. 2019Sep 1;30(9):1746\u201355.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"9124_CR17","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1681\/ASN.2015060688","volume":"27","author":"DMJ Naimark","year":"2016","unstructured":"Naimark DMJ, Grams ME, Matsushita K, Black C, Drion I, Fox CS, et al. Past decline versus current EGFR and subsequent mortality risk. J Am Soc Nephrol. 2016;27(8):2456\u201366.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"9124_CR18","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1007\/s00134-024-07560-y","volume":"50","author":"A Zarbock","year":"2024","unstructured":"Zarbock A, Forni LG, Koyner JL, Bell S, Reis T, Meersch M, et al. Recommendations for clinical trial design in acute kidney injury from the 31st acute disease quality initiative consensus conference. A consensus statement Intensive Care Med. 2024Sep 1;50(9):1426\u201337.","journal-title":"A consensus statement Intensive Care Med"},{"issue":"21","key":"9124_CR19","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2014.4952","volume":"311","author":"AX Garg","year":"2014","unstructured":"Garg AX, Devereaux PJ, Yusuf S, Cuerden MS, Parikh CR, Coca SG, et al. Kidney Function after off-pump or on-pump Coronary Artery Bypass Graft Surgery: A randomized clinical trial. JAMA. 2014Jun 4;311(21):2191\u20138.","journal-title":"JAMA"},{"issue":"2","key":"9124_CR20","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00134-023-07314-2","volume":"50","author":"M Meersch","year":"2024","unstructured":"Meersch M, Weiss R, Strau\u00df C, Albert F, Booke H, Forni L, et al. Acute kidney disease beyond day 7 after major surgery: a secondary analysis of the EPIS-AKI trial. Intensive Care Med. 2024Feb 1;50(2):247\u201357.","journal-title":"Intensive Care Med"},{"key":"9124_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2215\/CJN.00240605","volume":"1","author":"MH Rosner","year":"2006","unstructured":"Rosner MH, Okusa MD. Acute kidney injury associated with cardiac surgery. Clin J Am Soc Nephrol. 2006;1:19\u201332.","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09124-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-09124-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09124-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T02:02:46Z","timestamp":1761703366000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-09124-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9124"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-09124-x","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]},"assertion":[{"value":"17 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of the Physicians Chamber Westfalen-Lippe and the University of M\u00fcnster (=study site of Coordinating Investigator), along with relevant ethics committees or research ethics boards at participating sites, have approved the protocol, ICF and related documents.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"The participant is informed via the ICF that the results of the study, including their coded information, may also be presented at meetings or in publications and that their identity will remain confidential.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"AZ received consulting and lecture fees and grants from German Research Foundation, Guard Therapeutics, BioMerieux, Baxter, Fresenius, Paion, Viatris, Bayer, Novartis, Renibus, AM Pharma, and Alexion, and received meeting and travel support from Sphingotec. CDM received consulting fees from Alexion. TEL is a shareholder and employee of Guard Therapeutics. MR is a shareholder and paid consultant to Guard Therapeutics.AGI, AM, BdV, CS, JaB, JoB, and ML declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"449"}}